Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$24k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
6.8% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
2.0% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
1
users have commented on this narrative
16
users have followed this narrative
8 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.9% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
9
users have liked this narrative
2
users have commented on this narrative
13
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
American Well
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Digital Health Demand Will Accelerate Converge Platform Adoption
Key Takeaways Large government contracts, platform integration, and AI-driven efficiencies are positioning Amwell for long-term margin expansion and recurring software revenue growth. Shift toward digital-first healthcare and value-based models increases customer stickiness, expanding Amwell's market opportunity beyond traditional industry cycles.
View narrative
US$12.00
FV
40.8% undervalued
intrinsic discount
5.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Blink Charging
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Next-Gen Chargers Will Power Global EV And Grid Integration
Key Takeaways Blink's strategic site expansion, next-gen tech, and partnerships in energy management position it for superior network effects, recurring profits, and higher-margin growth. Accelerated cost controls, global manufacturing agility, and expanding government partnerships could rapidly drive profitability, scale, and upside to market expectations.
View narrative
US$5.00
FV
81.4% undervalued
intrinsic discount
36.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
PowerCell Sweden
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Global Decarbonization And Hydrogen Adoption Will Unlock New Markets
Key Takeaways Early EBITDA inflection and strong margin expansion are expected due to disciplined costs, operating leverage, and validated demand from major OEM partners. PowerCell's technology leadership, recurring revenues, and exposure to global zero-emission policies position it for accelerated growth, superior financing access, and higher long-term margins.
View narrative
SEK 50.00
FV
41.8% undervalued
intrinsic discount
20.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Innate Pharma
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Immuno-Oncology Advances And Biomarker Discoveries Will Drive Paradigm Shifts
Key Takeaways Disruptive clinical platforms and a strong pipeline position Innate for accelerated market capture, higher valuation, and potential major partnerships or acquisition interest. Innovative technology, regulatory momentum, and operational efficiency enable sustained margin expansion and resilience against funding challenges, supporting long-term earnings growth.
View narrative
€6.20
FV
67.5% undervalued
intrinsic discount
88.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Coherus Oncology
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Precision Medicine And Aging Markets Will Fuel Oncology Despite Setbacks
Key Takeaways Accelerated adoption, innovative pipeline, and first-to-market therapies may lead to higher-than-expected revenue growth and market leadership. Strategic international partnerships and focus on differentiated, precision oncology assets position the company for premium pricing, strong margins, and sustained global expansion.
View narrative
US$7.00
FV
84.7% undervalued
intrinsic discount
-21.17%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Hexagon Purus
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
US And German Incentives Will Expand Zero Emission Infrastructure
Key Takeaways Aggressive cost reductions and maintained production capacity position Hexagon Purus for rapid margin improvement and earnings rebound as market demand recovers. Portfolio diversification, strategic partnerships, and favorable policy shifts create multiple pathways for sustained revenue, recurring cash flow, and increased market resilience.
View narrative
NOK 6.20
FV
70.5% undervalued
intrinsic discount
48.55%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Cardlytics
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Digital Payments Adoption Will Expand Personalized Advertising In Fintech
Key Takeaways Cardlytics is positioned for accelerated growth through new partnerships, advanced analytics, and its unique access to large-scale transaction data. The platform's closed ecosystem and strong value proposition are set to drive advertiser budgets, margin expansion, and a greater share of loyalty-driven spending.
View narrative
US$2.00
FV
45.0% undervalued
intrinsic discount
-7.05%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
SoundThinking
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Global Expansion And Cloud Platforms Will Fuel Digital Policing
Key Takeaways Rapid international adoption and regulatory-driven expansion are expected to drive outsized recurring revenue growth and new high-margin opportunities across multiple sectors. Advanced AI development, strong partnerships, and a cloud-native portfolio position the company for increased contract values, higher renewal rates, and sustained margin improvement.
View narrative
US$29.22
FV
56.7% undervalued
intrinsic discount
10.99%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Sutro Biopharma
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Cell-Free Platform Will Unlock Broad Personalized Oncology Opportunities
Key Takeaways Strategic focus on advanced ADC programs and external manufacturing partnerships positions Sutro for accelerated revenue growth, high margins, and reduced dilution risk. Proprietary cell-free platform and pipeline strength enable leadership in personalized oncology, supporting premium pricing, diverse partnerships, and substantial expansion opportunities.
View narrative
US$7.00
FV
87.7% undervalued
intrinsic discount
1.96%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies